New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
13:36 EDTPBYIPuma presents 'positive' PB272 Phase II data from I-SPY 2 trial
Puma Biotechnology announced the presentation of "positive" results from the Phase II clinical trial of Puma's investigational drug PB272 for the neoadjuvant treatment of breast cancer, or I-SPY 2 trial, in an oral presentation. The presentation entitled “Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL” was presented today at the session entitled “Clinical Trials Symposium: Biomarker Driven Clinical Trials.” The I-SPY 2 TRIAL is a randomized Phase II clinical trial for women with newly diagnosed Stage 2 or higher breast cancer that addresses whether adding investigational drugs to standard chemotherapy in the neoadjuvant setting is better than standard chemotherapy. The primary endpoint is pathological complete response in the breast and the lymph nodes at the time of surgery. The goal of the trial is to match investigational regimens with patient subsets on the basis of molecular characteristics that benefit from the regimen. The trial enrolled patients who had a high risk of relapse using up-front tumor profiling.
News For PBYI From The Last 14 Days
Check below for free stories on PBYI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
07:12 EDTPBYIPuma Biotechnology neratinib use unlikely to be limited, says Citigroup
Although Puma's Neratinib breast cancer drug was enriched for high risk HER2+ patients during a recent trial, Citigroup does not expect its use to be restricted to high risk women. The firm keeps a $292 price target and Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use